The Post-Menopausal Osteoporosis Market was robust in 2021 and is expected to experience rapid revenue growth over the forecast period. The increasing prevalence of osteoporosis among menopausal women globally is driving the growth of the post-menopausal osteoporosis treatment market. However, the shortage of qualified experts and the side effects associated with treatment options are hindering the revenue growth of the market.

Osteoporosis is characterized by low bone mineral density (BMD) and microstructural degradation of bone tissue, leading to bone fragility. The World Health Organization (WHO) defines osteoporosis as having a T-score of less than or equal to 2.5, while osteopenia is defined as a T-score of 1.0 to 2.5. The lumbar spine and femoral neck are the anatomical regions of interest for diagnosis.

Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5519

There are several factors supporting the growth of the post-menopausal osteoporosis market. The prevalence of osteoporosis is increasing with age, with estimates showing that more than 50% of individuals over the age of 80 have osteoporosis. By 2050, it is projected that 6 million people worldwide will have osteoporosis, and 75% of them will live in developing nations. The availability of FDA-approved non-estrogen treatment options such as bisphosphonates and denosumab is driving the market.

Additionally, the aging population, particularly women, contributes to the growth of the market. In the United States alone, there are approximately 9.31 million menopausal women over the age of 50. The market benefits from the development of efficient and targeted treatments, as well as innovations in medication delivery, such as injectables and vitamin supplements for symptomatic relief. These factors contribute to the revenue growth of the post-menopausal osteoporosis market.

On the other hand, there are factors restraining the growth of the market. Various physical therapies available for the treatment of post-menopausal osteoporosis negatively affect the treatment market. Moreover, hormone replacement therapy, commonly used to treat osteoporosis, is associated with various side effects, including an increased risk of endometrial cancer. Guidelines suggest that hormone therapy is recommended for women at risk of osteoporotic fractures who are younger than 60 years old.

However, its use is not recommended solely for the prevention of fractures in women over 60 years old. The risk of side effects increases with higher doses and longer durations of usage. These factors impede the revenue growth of the post-menopausal osteoporosis treatment market.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/5519

The rise in research and development activities focused on the pharmaceutical treatment of post-menopausal osteoporosis presents opportunities for market growth. New non-estrogen medications are being developed for the treatment of osteoporosis. Increasing awareness and education about the disease can also be utilized as an opportunity to develop effective medications for post-menopausal osteoporosis patients.

In terms of the geographic market scenario, North America is expected to hold the largest revenue share over the forecast period. This can be attributed to the introduction of new treatment options and increased healthcare expenditures in the region. Additionally, awareness of the disease contributes to the revenue growth of the market. Asia Pacific is projected to experience significant revenue growth, driven by the increasing population diagnosed with post-menopausal osteoporosis in countries like China and India. The presence of targeted drug manufacturers and the expansion of healthcare facilities also contribute to the market growth in the region.

In terms of market trends and innovation, ongoing studies are comparing the effectiveness of FDA-approved medications, Ramucirumab and Denosumab, in treating osteoporosis. Additionally, there are various organic and inorganic strategies being adopted by companies in the market. For instance, the Pre-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients with Postmenopausal Osteoporosis was conducted as of August 2022. Furthermore, the competitive landscape includes major companies such as Amgen Inc., Clonz Biotech, Eli Lilly and Company, Enteris BioPharma, Ligand Pharmaceuticals Incorporated, Merck Co., Inc., Outlook Therapeutics, Inc., and Paras Biopharmaceuticals.

In conclusion, this report provides historical data, forecasts, and analysis of the post-menopausal osteoporosis treatment market at a global, regional, and country level. It covers industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and the competitive landscape. The report also includes end-use outlook, distribution channel outlook, route of administration outlook, treatment outlook, and regional outlook. It offers valuable insights for stakeholders and researchers in the field of post-menopausal osteoporosis treatment.

Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5519

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.

Browse for more reports:

https://www.reportsanddata.com/report-detail/medical-specialty-bags-market

https://www.reportsanddata.com/report-detail/teleradiology-market

https://www.reportsanddata.com/report-detail/therapeutic-drug-monitoring-market

https://www.reportsanddata.com/report-detail/electrophysiology-devices-market

https://www.reportsanddata.com/report-detail/vascular-closure-devices-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[email protected]

Blogs|Press Release|Industry News|Our competencies

Browse MoreUpcoming Reports @https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @https://www.reportsanddata.com/report